NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (OSRAM) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (OSRAM)
EP (6) EP1880735A3 (OSRAM)
JP (4) JP4846906B2 (OSRAM)
KR (3) KR100798212B1 (OSRAM)
CN (3) CN100339130C (OSRAM)
AR (3) AR022965A1 (OSRAM)
AT (3) ATE346608T1 (OSRAM)
AU (3) AU750913B2 (OSRAM)
BE (1) BE1025464I2 (OSRAM)
BR (4) BR0009154A (OSRAM)
CA (3) CA2365296A1 (OSRAM)
CY (3) CY1107561T1 (OSRAM)
CZ (3) CZ303653B6 (OSRAM)
DE (4) DE60032120T2 (OSRAM)
DK (2) DK1162999T3 (OSRAM)
ES (3) ES2339737T3 (OSRAM)
FR (1) FR10C0008I2 (OSRAM)
HK (3) HK1043730A1 (OSRAM)
HU (4) HUP0200664A2 (OSRAM)
IL (5) IL145043A0 (OSRAM)
LU (1) LU91652I2 (OSRAM)
MX (1) MXPA01009452A (OSRAM)
MY (2) MY125387A (OSRAM)
NL (1) NL300415I1 (OSRAM)
NO (4) NO20014322L (OSRAM)
NZ (3) NZ513840A (OSRAM)
PL (3) PL204890B1 (OSRAM)
PT (2) PT1163000E (OSRAM)
SI (2) SI1163000T1 (OSRAM)
TR (3) TR200102736T2 (OSRAM)
TW (3) TWI281403B (OSRAM)
WO (3) WO2000056358A2 (OSRAM)

Families Citing this family (289)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
DK1355673T3 (da) * 2001-01-23 2012-09-17 Sanofi Pasteur Inc Multivalent meningococvaccine bestƄende af et polysaccharid/proteinkonjugat
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
JP4413617B2 (ja) 2001-12-12 2010-02-10 ć‚«ć‚¤ćƒ­ćƒ³ ć‚½ćƒć‚Øć‚æ ć‚¢ ćƒ¬ć‚¹ćƒćƒ³ć‚µćƒ“ćƒŖć‚æ ćƒŖ惟ć‚æćƒ¼ć‚æ ļ¼£ļ½ˆļ½Œļ½ļ½ļ½™ļ½„ļ½‰ļ½ļ½”ļ½’ļ½ļ½ƒļ½ˆļ½ļ½ļ½ļ½”ļ½‰ļ½“恫åÆ¾ć™ć‚‹å…ē–«åŒ–
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthƤlt
EP1506007B1 (en) * 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE047780T2 (hu) 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinĆ”k hipervirulens meningokokkusz vonalak elleni szĆ©les-spektrumĆŗ vĆ©delemre
WO2004035618A2 (en) * 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
WO2004039399A1 (en) 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN100351260C (zh) 2002-11-12 2007-11-28 åøƒčµ–ę±‰å§†å¦‡å„³åŒ»é™¢ 葔萄ēƒčŒę„ŸęŸ“ēš„多ē³–ē–«č‹—
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP2006512927A (ja) 2002-12-11 2006-04-20 ć‚³ćƒ¼ćƒŖćƒ¼ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ« ć‚°ćƒ«ćƒ¼ćƒ—ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼•ā€™ļ½ƒļ½ļ½‡ę øé…øćŠć‚ˆć³ćć®ä½æē”Øę–¹ę³•
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra mĆŗltiples serogrupos de meningococos
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
JP4597123B2 (ja) * 2003-03-13 2010-12-15 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ē“°čŒę€§ē“°čƒžęŗ¶č§£ē“ ć®ē²¾č£½ę–¹ę³•
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1961426B1 (en) * 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
JP2008504292A (ja) 2004-06-24 2008-02-14 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ļ¼Œ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ 免ē–«å¢—å¼·ē”Øć®åŒ–åˆē‰©
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP4993750B2 (ja) 2005-01-27 2012-08-08 ćƒćƒ«ćƒ‰ćƒ¬ćƒ³ć‚ŗ ćƒ›ć‚¹ćƒ”ć‚æ惫 ć‚¢ćƒ³ćƒ‰ ćƒŖć‚µćƒ¼ćƒ ć‚»ćƒ³ć‚æćƒ¼ ć‚¢ćƒƒćƒˆ ć‚Ŗćƒ¼ć‚Æćƒ©ćƒ³ćƒ‰ é«„č†œē‚ŽčŒć«čµ·å› ć™ć‚‹ē–¾ę‚£ć«åÆ¾ć™ć‚‹åŗƒåŸŸé˜²å¾”ć®ćŸć‚ć®ć€ļ½‡ļ½Žļ½ļ¼‘ļ¼˜ļ¼—ļ¼ć‚’åŸŗć«ć—ćŸå°čƒžćƒÆć‚Æćƒćƒ³
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
DK1858919T3 (da) 2005-02-18 2012-07-16 Novartis Vaccines & Diagnostic Immunogener fra uropathogen Escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (zh) 2005-04-08 2023-03-21 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø 多价č‚ŗē‚ŽēƒčŒå¤šē³–-蛋ē™½č“Øē¼€åˆē‰©ē»„合ē‰©
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
KR20130122810A (ko) 2005-06-27 2013-11-08 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė°±ģ‹  ģ œģ”° ė°©ė²•
BRPI0615420A2 (pt) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinaĆ§Ć£o mĆŗltipla que inclui meningococo do sorogrupo c
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
DK2384765T3 (en) * 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
JP5275814B2 (ja) * 2006-01-17 2013-08-28 惕ć‚Ŗćƒ«ć‚¹ćƒ¬ćƒ³ļ¼Œć‚¢ćƒ«ćƒ ę–°č¦č”Ø面露å‡ŗćƒ˜ćƒ¢ćƒ•ć‚£ćƒ«ć‚¹ćƒ»ć‚¤ćƒ³ćƒ•ćƒ«ć‚Øćƒ³ć‚¶ļ¼ˆļ¼Øļ¼”ļ¼„ļ¼­ļ¼Æļ¼°ļ¼Øļ¼©ļ¼¬ļ¼µļ¼³ļ¼©ļ¼®ļ¼¦ļ¼¬ļ¼µļ¼„ļ¼®ļ¼ŗļ¼”ļ¼„ļ¼‰ć‚æćƒ³ćƒ‘ć‚Æč³Ŗļ¼ˆć‚æćƒ³ćƒ‘ć‚Æč³Ŗļ¼„ļ¼›ļ½ļ¼„ļ¼‰
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
BRPI0708849B1 (pt) * 2006-03-17 2022-05-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services MĆ©todos para a preparaĆ§Ć£o de conjugados imunogĆŖnicos multivalentes complexos, os referidos conjugados, e composiƧƵes farmacĆŖuticas
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2670231T3 (es) 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. RegĆ­menes para inmunizaciĆ³n con conjugados meningocĆ³cicos
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
MY148405A (en) * 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
PE20080129A1 (es) * 2006-03-30 2008-04-08 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhƦsiner
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
MX2009003730A (es) * 2006-10-10 2009-04-22 Wyeth Corp Purificacion de polisacaridos de streptococcus pneumoniae tipo 3.
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
PL2167121T3 (pl) * 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
JP5653215B2 (ja) 2007-09-12 2015-01-14 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼§ļ½ļ½“ļ¼•ļ¼—変ē•°ä½“ęŠ—åŽŸćŠć‚ˆć³ļ½‡ļ½ļ½“ļ¼•ļ¼—ęŠ—ä½“
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag FormulaƧƵes de vacinas meningocĆ³cicas
JP2011503104A (ja) 2007-11-09 2011-01-27 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒ†ćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 免ē–«čŖæēƀ化合ē‰©ćŖć‚‰ć³ć«é–¢é€£ēµ„ęˆē‰©ćŠć‚ˆć³ę–¹ę³•
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducciĆ³n de respuestas inmunes
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
DK2235046T3 (da) 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O
AU2009208403A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
RU2475496C2 (ru) 2008-02-21 2013-02-20 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ ŠœŠ•ŠŠ˜ŠŠ“ŠžŠšŠžŠšŠšŠžŠ’Š«Š• ŠŸŠžŠ›Š˜ŠŸŠ•ŠŸŠ¢Š˜Š”Š« fHBP
CA2717870A1 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CA2731384C (en) 2008-07-21 2015-03-10 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa MĆ©todo de purificaĆ§Ć£o para hidrato de carbono de estreptococos grupo a
MX337723B (es) 2008-12-09 2016-03-15 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
EP2384120B1 (en) 2009-01-05 2019-12-11 Epitogenesis Inc. Adjuvant compositions and methods of use
CN102481349B (zh) 2009-01-12 2014-10-15 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø ęŠ—é©å…°ę°é˜³ę€§ē»†čŒē–«č‹—äø­ēš„Cna_Bē»“ęž„åŸŸ
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
NZ595291A (en) 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010119343A2 (en) 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
JP5395264B2 (ja) 2009-06-22 2014-01-22 ćƒÆć‚¤ć‚¹ćƒ»ć‚Ø惫ć‚Øćƒ«ć‚·ćƒ¼ é»„č‰²ćƒ–ćƒ‰ć‚¦ēƒčŒļ¼ˆļ½“ļ½”ļ½ļ½ļ½ˆļ½™ļ½Œļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½•ļ½’ļ½…ļ½•ļ½“ļ¼‰ęŠ—åŽŸć®å…ē–«åŽŸę€§ēµ„ęˆē‰©
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
RU2518291C2 (ru) 2009-07-30 2014-06-10 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š’эŠŗсŠøŠ½Ń Š­Š»Š­Š»Š”Šø ŠŠ½Ń‚ŠøŠ³ŠµŠ½Š½Ń‹Šµ tau-ŠæŠµŠæтŠøŠ“ы Šø Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptĆ­dios hĆ­bridos incluindo sequĆŖncias meningocĆ³cicas de fhbp
MY163512A (en) * 2009-09-03 2017-09-15 Pfizer Vaccines Llc Pcsk9 vaccine
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011051917A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SG181750A1 (en) * 2009-12-17 2012-07-30 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
NZ600978A (en) 2009-12-22 2014-08-29 Celldex Therapeutics Inc Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Ɩzellikleri değiştirilmiş faktƶr h bağlama proteinleri (fhbp) ve bunların kullanım yƶntemi.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
ES2694100T3 (es) 2010-04-07 2018-12-18 California Institute Of Technology VehĆ­culo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
JP2013530949A (ja) * 2010-05-20 2013-08-01 ć‚Ø惫 ćƒ©ć‚¦ćƒ³ćƒ‰ ć‚øćƒ„ćƒ¼ćƒ³ ęŠ—åŽŸē‰¹ē•°ēš„ļ¼“ļ½’ļ½…ļ½‡äø¦ć³ć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•åŠć³ć‚·ć‚¹ćƒ†ćƒ 
KR20130121699A (ko) 2010-05-28 2013-11-06 ķ…ŒķŠøė¦¬ģŠ¤ ģ˜Øė¼ģø, ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģƒķ˜øģž‘ģš© ķ˜¼ģ„± ė¹„ė™źø° ģ»“ķ“Øķ„° ź²Œģž„ źø°ė°˜źµ¬ģ”°
ES2614807T3 (es) * 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
UA111845C2 (uk) 2011-05-06 2016-06-24 ŠŸŃŒŠ¾Ń‚Ń€ Š“Ń”Š½Š½Š°Š“ьєŠ²Ń–ч ŠŠæŠ°Ń€Ń–Š½ Š•ŠŗŠ·Š¾ŠæŠ¾Š»Ń–сŠ°Ń…Š°Ń€ŠøŠ“ Š±Š°ŠŗтŠµŃ€Ń–Ń— shigella sonnei, сŠæŠ¾ŃŃ–Š± Š¹Š¾Š³Š¾ Š¾Š“ŠµŃ€Š¶Š°Š½Š½Ń тŠ° Š²Š°ŠŗцŠøŠ½Š° і фŠ°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠ½Š° ŠŗŠ¾Š¼ŠæŠ¾Š·Šøція, щŠ¾ Š¹Š¾Š³Š¾ Š¼Ń–ŃŃ‚ŃŃ‚ŃŒ
WO2012178118A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
CN103974718A (zh) 2011-12-08 2014-08-06 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø åŸŗäŗŽč‰°éš¾ę¢­čŒęƒē“ ēš„ē–«č‹—
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
AU2011384634A1 (en) 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
CN104519910B (zh) 2012-03-07 2017-05-03 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒęŠ—原ēš„含佐剂制剂
JP2015509963A (ja) 2012-03-08 2015-04-02 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼“ļ½Œļ½’ļ¼”ć‚¢ć‚“ćƒ‹ć‚¹ćƒˆć‚’å«ć‚€ę··åˆćƒÆć‚Æćƒćƒ³
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CN104321078A (zh) 2012-04-26 2015-01-28 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø ęŠ—åŽŸå’ŒęŠ—åŽŸē»„合
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
ES2820898T3 (es) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos
KR102057217B1 (ko) * 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
CN104602705A (zh) 2012-09-06 2015-05-06 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 蔀ęø…ē»„b脑膜ē‚ŽēƒčŒå’Œd/t/pēš„č”åˆē–«č‹—
KR20150073943A (ko) 2012-10-03 2015-07-01 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
EP3620172A1 (en) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
SG11201502635SA (en) * 2012-10-17 2015-05-28 Glaxosmithkline Biolog Sa Immunogenic composition
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa AdministraciĆ³n intradĆ©rmica de composiciones inmunolĆ³gicas que comprenden agonistas del receptor de tipo Toll
JP2016521284A (ja) 2013-05-10 2016-07-21 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 大č…øć‚¬ćƒ³ć®ćƒ—ćƒ­ćƒć‚¤ć‚Ŗćƒ†ć‚£ć‚Æć‚¹ć«ć‚ˆć‚‹é˜²ę­¢ćŠć‚ˆć³å‡¦ē½®
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composiƧƵes de neisseria meningitidis e mƩtodos das mesmas
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
NZ721943A (en) 2014-01-21 2022-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
RU2710393C2 (ru) 2014-01-21 2019-12-26 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š˜Š½Šŗ. Š”ŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя ŠøŠ¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Š¾Š³Š¾ ŠŗŠ¾Š½ŃŠŃŽŠ³Š°Ń‚Š° ŠŗŠ°ŠæсуŠ»ŃŒŠ½Ń‹Š¹ ŠæŠ¾Š»ŠøсŠ°Ń…Š°Ń€ŠøŠ“ Streptococcus pneumoniae-Š±ŠµŠ»Š¾Šŗ-Š½Š¾ŃŠøтŠµŠ»ŃŒ
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
WO2016014719A1 (en) 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Factor h binding protein variants and methods of use thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
RU2018104362A (ru) 2015-07-07 2019-08-08 ŠŃ„Ń„ŠøрŠøс ŠŠ³ Š’ŠŠšŠ¦Š˜ŠŠ« Š”Š›ŠÆ Š›Š•Š§Š•ŠŠ˜ŠÆ Š˜ ŠŸŠ ŠžŠ¤Š˜Š›ŠŠšŠ¢Š˜ŠšŠ˜ Š—ŠŠ‘ŠžŠ›Š•Š’ŠŠŠ˜Š™, ŠžŠŸŠžŠ”Š Š•Š”ŠžŠ’ŠŠŠŠ«Š„ IgE
TWI756893B (zh) 2015-07-21 2022-03-01 ē¾Žå•†č¼ē‘žč‚”ä»½ęœ‰é™å…¬åø 包含ē¶“å…±č»›ä¹‹čŽ¢č†œē³–ęŠ—åŽŸēš„臓免ē–«ę€§ēµ„ęˆē‰©ć€åŒ…å«č©²č‡“免ē–«ę€§ēµ„ęˆē‰©ä¹‹å„—ēµ„及彼ē­‰ä¹‹ē”Ø途
EP3341017B1 (en) 2015-08-25 2024-10-16 Babita Agrawal Immunomodulatory compositions comprising caulobacter crescentus and use thereof
WO2017060857A1 (en) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ č‚ŗē‚Žé€£éŽ–ēƒčŒćƒÆć‚Æćƒćƒ³ć«ćŠć„ć¦ē”Øć„ć‚‹ćŸć‚ć®å…ē–«åŽŸę€§ēµ„ęˆē‰©
CR20180350A (es) 2015-12-04 2018-10-02 Dana Farber Cancer Inst Inc VacunaciĆ³n con el dominio alfa 3 de mica/b para el tratamiento del cĆ”ncer
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
PT3405212T (pt) 2016-01-19 2020-08-25 Pfizer Vacinas para o cancro
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
EP3474890A1 (en) * 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Fƶrderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
JP7001686B2 (ja) 2016-08-05 2022-02-04 ć‚µćƒŽćƒ•ć‚£ ćƒ‘ć‚¹ćƒ„ćƒ¼ćƒ« ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ć‚£ćƒƒćƒ‰ 多侔č‚ŗē‚ŽēƒčŒå¤šē³–体ļ¼ć‚æćƒ³ćƒ‘ć‚Æč³Ŗć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆēµ„ęˆē‰©
CN109862908B (zh) 2016-08-05 2023-05-02 圣čÆŗč²Ā·åø•ę–Æ图尔公åø 多价č‚ŗē‚ŽēƒčŒå¤šē³–-蛋ē™½č“Øē¼€åˆē‰©ē»„合ē‰©
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
KR102686875B1 (ko) 2016-10-07 2024-07-19 ģ—”ķ„°ė”¬ ģ—ģŠ¤.ģ—ģ“. ģ•” ģ¹˜ė£Œė„¼ ģœ„ķ•œ ė©“ģ—­ģ›ģ„± ķ™”ķ•©ė¬¼
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
AU2018208844B2 (en) 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN118021947A (zh) 2017-01-31 2024-05-14 č¾‰ē‘žå¤§čÆ厂 脑膜ē‚Žå„ˆē‘ŸčŒē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
WO2018169303A1 (ko) * 2017-03-15 2018-09-20 ģ£¼ģ‹ķšŒģ‚¬ ģ—˜ģ§€ķ™”ķ•™ ė‹¤ź°€ ķė “źµ¬ź·  ė°±ģ‹  ģ”°ģ„±ė¬¼
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
KR20240018698A (ko) 2017-06-10 2024-02-13 ģøė²¤ķŠøķ”„ė¼ģ“ģ¦ˆ ģøķ¬. ė©“ģ—­ģ›ģ„±ź³¼ ķ•­ģ›ķ•­ģ²“ ź²°ķ•©ģ„±ģ“ ź°œģ„ ėœ 2ź°€ ė˜ėŠ” ė‹¤ź°€ ģ ‘ķ•©ģ²“ ė‹¤ė‹¹ė„˜ė„¼ ź°€ģ§„ ė‹¤ź°€ ģ ‘ķ•©ģ²“ ė°±ģ‹ 
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. mĆ©todo de reforƧar uma resposta imune prĆ©-existente contra haemophilus influenzae e moraxella catarrhalis nĆ£o tipĆ”veis em um indivĆ­duo, e, protocolo de vacinaĆ§Ć£o.
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR102812816B1 (ko) 2018-02-05 2025-05-27 ģ‚¬ė…øķ”¼ ķŒŒģŠ¤ķ‡“ė„“ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‹¤ź°€ ķė “źµ¬ź· ģ„± ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
IL276230B2 (en) 2018-02-05 2024-01-01 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
CA3094262A1 (en) 2018-04-11 2019-10-17 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
US11951162B2 (en) 2018-04-18 2024-04-09 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
JP7446279B2 (ja) 2018-07-19 2024-03-08 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ä¹¾ē‡„多ē³–ć‚’čŖæč£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
JP2021533162A (ja) 2018-08-07 2021-12-02 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ćƒ—ćƒ­ć‚»ć‚¹åŠć³ćƒÆć‚Æćƒćƒ³
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
BR112021011961A8 (pt) 2018-12-19 2023-02-07 Merck Sharp & Dohme ComposiƧƵes compreendendo conjugados de polissacarƭdeo-proteƭna de streptococcus pneumoniae e mƩtodos de uso dos mesmos
JP7644454B2 (ja) * 2019-01-11 2025-03-12 ćƒŽćƒ¼ć‚¹ć‚¦ć‚§ć‚¹ć‚æćƒ³ ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ 原ę øē“°čƒžęŗ¶č§£ē‰©ć«ćŠć‘ć‚‹ćƒć‚¤ć‚Ŗć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆćƒÆć‚Æćƒćƒ³ć®åˆęˆ
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
MX2021013736A (es) 2019-05-10 2021-12-10 Glaxosmithkline Biologicals Sa Produccion de conjugados.
MX2022001488A (es) 2019-08-05 2022-03-02 Glaxosmithkline Biologicals Sa Composicion inmunogenica.
BR112021026775A2 (pt) 2019-08-05 2022-05-10 Glaxosmithkline Biologicals Sa Processo para preparar uma composiĆ§Ć£o que compreende um polipeptĆ­deo de proteĆ­na d
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
EP4045150B1 (en) 2019-10-16 2025-11-26 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
CA3153470A1 (en) 2019-11-15 2021-05-20 Laurent Chene Antigenic peptides for prevention and treatment of b-cell malignancy
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
EP4107192A1 (en) 2020-02-21 2022-12-28 Pfizer Inc. Purification of saccharides
BR112022014555A2 (pt) 2020-02-23 2022-09-20 Pfizer ComposiƧƵes de escherichia coli e mƩtodos das mesmas.
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
EP4165064A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230097160A (ko) 2020-11-04 2023-06-30 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ķė “źµ¬ź·  ė°±ģ‹ ģ— ģ‚¬ģš©ķ•˜źø° ģœ„ķ•œ ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
AU2022223712A1 (en) 2021-02-19 2023-10-05 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230175284A (ko) 2021-05-28 2023-12-29 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ ‘ķ•©ėœ ķ”¼ė§‰ ģ‚¬ģ¹“ė¼ģ“ė“œ ķ•­ģ›ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ģš©ė„
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
IL314243A (en) 2022-01-13 2024-09-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
US20250205324A1 (en) 2022-03-31 2025-06-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
CA3256617A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121038808A (zh) 2023-03-30 2025-11-28 č¾‰ē‘žå…¬åø 包含ē¼€åˆēš„čšč†œē³–ęŠ—åŽŸēš„免ē–«åŽŸę€§ē»„合ē‰©åŠå…¶ē”Ø途
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP3237842B2 (ja) * 1988-12-16 2001-12-10 ć‚Ŗćƒ©ćƒ³ćƒ€å›½ ćƒ‹ćƒ„ćƒ¼ćƒ¢ćƒŖć‚·ćƒ³ćƒŸćƒ„ćƒ¼ć‚æćƒ³ćƒˆåŠć³ćć‚Œć‹ć‚‰č£½é€ ć•ć‚ŒćŸćƒ‹ćƒ„ćƒ¼ćƒ¢ć‚³ćƒƒć‚«ćƒ«ćƒÆć‚Æćƒćƒ³
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
WO1994006465A1 (en) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Antigen of hybrid m protein and carrier for group a streptococcal vaccine
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
DE69431624T2 (de) 1993-05-18 2003-07-10 The Ohio State University Research Foundation, Columbus Impfstoff gegen mittelohrentzĆ¼ndung
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
WO1996032963A1 (en) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
CA2224015A1 (en) 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
ATE400295T1 (de) 1995-06-07 2008-07-15 Glaxosmithkline Biolog Sa Vakzine mit einem polysaccharide antigen- trƤgerprotein konjugat und freiem trƤgerprotein
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
WO1997041151A2 (en) 1996-05-01 1997-11-06 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
EP1000144B1 (en) 1997-06-03 2007-12-12 Sanofi Pasteur Limited Lactoferrin receptor gene of moraxella
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
IL138798A0 (en) 1998-04-07 2001-10-31 Medimmune Inc Vaccines and antibodies against bacterial pneumococcal infection
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CN1263510C (zh) 1998-08-19 2006-07-12 å·“å…‹ę–Æē‰¹å„åŗ·ęŠ¤ē†č‚”ä»½ęœ‰é™å…¬åø 多ē³–ļ¼č›‹ē™½č“Øē¼€åˆē‰©ęˆ–åÆ”ē³–ļ¼č›‹ē™½č“Øē¼€åˆē‰©ć€å…¶åˆ¶å¤‡ę–¹ę³•åŠå…¶åŗ”ē”Ø
PT1140157E (pt) * 1998-12-21 2009-05-06 Medimmune Inc Proteƭnas de streptococcus pneumoniae e fragmentos imunogƩnicos para vacinas
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
CN1351503A (zh) 2002-05-29
IL145045A0 (en) 2002-06-30
CZ20013378A3 (cs) 2002-03-13
NO330532B1 (no) 2011-05-09
DE60043930D1 (de) 2010-04-15
JP2011057713A (ja) 2011-03-24
TWI235064B (en) 2005-07-01
WO2000056360A3 (en) 2001-01-25
PL355180A1 (en) 2004-04-05
NO20014323D0 (no) 2001-09-05
HK1043728A1 (en) 2002-09-27
WO2000056360A2 (en) 2000-09-28
ATE346608T1 (de) 2006-12-15
JP2002540075A (ja) 2002-11-26
WO2000056359A3 (en) 2001-02-01
NO2011014I2 (no) 2011-08-30
SI1162999T1 (sl) 2007-04-30
ES2339737T3 (es) 2010-05-25
DE60038166D1 (de) 2008-04-10
US9168313B2 (en) 2015-10-27
BR0009166A (pt) 2001-12-26
CN1192798C (zh) 2005-03-16
BRPI0009163B1 (pt) 2019-04-09
EP1162999A2 (en) 2001-12-19
NL300415I1 (nl) 2009-12-01
BR0009163A (pt) 2001-12-26
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
MXPA01009452A (es) 2002-08-06
HU228499B1 (en) 2013-03-28
IL145043A (en) 2007-06-17
HUP0200664A2 (en) 2002-06-29
EP2277535A3 (en) 2011-03-09
CZ20013379A3 (cs) 2002-03-13
CN1191852C (zh) 2005-03-09
HUP0200367A2 (en) 2002-05-29
HK1043730A1 (zh) 2002-09-27
IL145044A0 (en) 2002-06-30
ATE459373T1 (de) 2010-03-15
AR022963A1 (es) 2002-09-04
EP1880735A2 (en) 2008-01-23
AU750913B2 (en) 2002-08-01
AU3430700A (en) 2000-10-09
CZ303653B6 (cs) 2013-01-30
JP5551579B2 (ja) 2014-07-16
AR022965A1 (es) 2002-09-04
ATE387214T1 (de) 2008-03-15
EP1163000B1 (en) 2008-02-27
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
NO20014325D0 (no) 2001-09-05
US20060093626A1 (en) 2006-05-04
EP1162998B1 (en) 2010-03-03
NO2011014I1 (no) 2011-09-19
KR20020001785A (ko) 2002-01-09
HU229968B1 (hu) 2015-03-30
SI1163000T1 (sl) 2008-06-30
US20110217329A1 (en) 2011-09-08
CY1107561T1 (el) 2013-03-13
BE1025464I2 (OSRAM) 2019-03-06
KR20020000549A (ko) 2002-01-05
FR10C0008I1 (fr) 2010-03-26
LU91652I9 (OSRAM) 2019-01-03
EP1162999B1 (en) 2006-11-29
CN1391481A (zh) 2003-01-15
TR200102735T2 (tr) 2002-04-22
BRPI0009163B8 (pt) 2021-05-25
NO20014325L (no) 2001-11-14
IL145043A0 (en) 2002-06-30
JP2002540074A (ja) 2002-11-26
DK1163000T3 (da) 2008-04-28
US8926985B2 (en) 2015-01-06
BR0009154A (pt) 2001-12-26
TWI286938B (en) 2007-09-21
PL203917B1 (pl) 2009-11-30
FR10C0008I2 (fr) 2012-10-26
TWI281403B (en) 2007-05-21
NO20014322L (no) 2001-11-14
US20050031646A1 (en) 2005-02-10
CY2009014I1 (el) 2010-07-28
HUS1500040I1 (hu) 2018-05-28
CY1107390T1 (el) 2010-07-28
KR100798212B1 (ko) 2008-01-24
TR200102736T2 (tr) 2002-04-22
EP1880735A3 (en) 2008-03-12
DE60038166T2 (de) 2009-03-12
HK1043728B (en) 2007-06-22
PL355178A1 (en) 2004-04-05
CN1351501A (zh) 2002-05-29
EP2277535A2 (en) 2011-01-26
DE122009000054I1 (de) 2009-12-31
HUP0200373A2 (en) 2002-06-29
NO330736B1 (no) 2011-06-27
NZ513840A (en) 2004-02-27
KR20020000785A (ko) 2002-01-05
EP1163000A2 (en) 2001-12-19
JP2002539273A (ja) 2002-11-19
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
MY125202A (en) 2006-07-31
JP4846906B2 (ja) 2011-12-28
WO2000056359A2 (en) 2000-09-28
KR100642044B1 (ko) 2006-11-10
CZ301445B6 (cs) 2010-03-03
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
US20030147922A1 (en) 2003-08-07
AU3813600A (en) 2000-10-09
CA2366314A1 (en) 2000-09-28
WO2000056358A2 (en) 2000-09-28
AR022964A1 (es) 2002-09-04
NZ513841A (en) 2001-09-28
CA2365296A1 (en) 2000-09-28
AU750762B2 (en) 2002-07-25
US20060002961A1 (en) 2006-01-05
ES2300255T3 (es) 2008-06-16
TR200102739T2 (tr) 2001-12-21
DK1162999T3 (da) 2007-03-26
AU750788B2 (en) 2002-07-25
EP1776962A1 (en) 2007-04-25
EP1162998A2 (en) 2001-12-19
DE60032120T2 (de) 2007-09-20
PT1162999E (pt) 2007-02-28
CY2009014I2 (el) 2010-07-28
NZ513842A (en) 2004-05-28
WO2000056358A3 (en) 2001-01-04
MY125387A (en) 2006-07-31
US20100119544A1 (en) 2010-05-13
PL355264A1 (en) 2004-04-05
NO20014322D0 (no) 2001-09-05
DE60032120D1 (de) 2007-01-11
AU3291900A (en) 2000-10-09
HK1043731A1 (en) 2002-09-27
LU91652I2 (fr) 2010-10-13
IL145044A (en) 2007-03-08
HK1043731B (en) 2009-01-23
PL204890B1 (pl) 2010-02-26
CA2366314C (en) 2012-01-10

Similar Documents

Publication Publication Date Title
BE2015C018I2 (OSRAM)
BE2014C017I2 (OSRAM)
BE2013C051I2 (OSRAM)
BE2013C020I2 (OSRAM)
BE2013C015I2 (OSRAM)
BE2013C001I2 (OSRAM)
BE2012C036I2 (OSRAM)
BE1025464I2 (OSRAM)
BE2008C046I2 (OSRAM)
BE2010C011I2 (OSRAM)
JP2002514480A5 (OSRAM)
IN2001KO01233A (OSRAM)
JP2002521141A5 (OSRAM)
BE2008C047I2 (OSRAM)
BE2011C004I2 (OSRAM)
JP2002521591A5 (OSRAM)
JP2002517184A5 (OSRAM)
JP2002519925A5 (OSRAM)
JP2002513244A5 (OSRAM)
JP2002506962A5 (OSRAM)
JP2002521163A5 (OSRAM)
JP2002513606A5 (OSRAM)
JP2002502016A5 (OSRAM)
JP2002522346A5 (OSRAM)
HU0004772D0 (OSRAM)